Uncategorized
NICE recommends Ozurdex for pseudophakic patients with DME
The U.K. National Institute for Health and Care Excellence has issued guidance recommending the use of Ozurdex for a particular group of patients with diabetic macular edema, Allergan announced in a press release. The NICE Technology Appraisal Guidance recommended Ozurdex (dexamethasone intravitreal implant 0.7 mg, Allergan) for people with visual impairment due to DME who have an artificial lens and are considered insufficiently responsive to or unsuitable for non-corticosteroid therapy. Within 3 months, Ozurdex will be made available by the NHS.